Stemline Therapeutics (STML) Reaches New 1-Year Low After Earnings Miss

Stemline Therapeutics Inc (NASDAQ:STML)’s share price hit a new 52-week low during trading on Friday after the company announced weaker than expected quarterly earnings. The company traded as low as $12.60 and last traded at $13.25, with a volume of 19991 shares traded. The stock had previously closed at $14.58.

The biopharmaceutical company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.06).

A number of equities analysts have issued reports on the company. BidaskClub cut Stemline Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday, November 2nd. ValuEngine cut Stemline Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Saturday. HC Wainwright set a $38.00 price target on Stemline Therapeutics and gave the stock a “buy” rating in a report on Friday, August 10th. Finally, Zacks Investment Research upgraded Stemline Therapeutics from a “sell” rating to a “hold” rating in a report on Thursday, August 16th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company. The company presently has an average rating of “Buy” and an average price target of $30.00.

Several institutional investors have recently bought and sold shares of the business. BlackRock Inc. increased its position in Stemline Therapeutics by 6.3% during the third quarter. BlackRock Inc. now owns 1,969,492 shares of the biopharmaceutical company’s stock valued at $32,694,000 after acquiring an additional 116,672 shares during the last quarter. Northern Trust Corp increased its position in Stemline Therapeutics by 12.5% during the second quarter. Northern Trust Corp now owns 380,378 shares of the biopharmaceutical company’s stock valued at $6,106,000 after acquiring an additional 42,262 shares during the last quarter. Millennium Management LLC increased its position in Stemline Therapeutics by 169.3% during the second quarter. Millennium Management LLC now owns 161,735 shares of the biopharmaceutical company’s stock valued at $2,596,000 after acquiring an additional 101,679 shares during the last quarter. Nexthera Capital LP increased its position in Stemline Therapeutics by 6.9% during the second quarter. Nexthera Capital LP now owns 559,517 shares of the biopharmaceutical company’s stock valued at $8,980,000 after acquiring an additional 35,893 shares during the last quarter. Finally, Bank of America Corp DE increased its position in Stemline Therapeutics by 97.8% during the second quarter. Bank of America Corp DE now owns 20,548 shares of the biopharmaceutical company’s stock valued at $329,000 after acquiring an additional 10,159 shares during the last quarter. Hedge funds and other institutional investors own 67.17% of the company’s stock.

The stock has a market cap of $462.77 million, a P/E ratio of -4.49 and a beta of 0.58.

ILLEGAL ACTIVITY WARNING: “Stemline Therapeutics (STML) Reaches New 1-Year Low After Earnings Miss” was first posted by WKRB News and is the sole property of of WKRB News. If you are viewing this piece on another website, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The correct version of this piece can be accessed at https://www.wkrb13.com/2018/11/11/stemline-therapeutics-stml-reaches-new-1-year-low-after-earnings-miss.html.

Stemline Therapeutics Company Profile (NASDAQ:STML)

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

See Also: Risk Tolerance

Receive News & Ratings for Stemline Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stemline Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply